Surgical oncology

Coeptis Therapeutics Enters Exclusive License Agreement with University of Pittsburgh for Rights to SNAP-CAR, a "Multi-Antigen" CAR T Technology

Retrieved on: 
Wednesday, September 21, 2022
Securities Exchange Act of 1934, National, Pitt, Surgical oncology, Breast, Engineering, Assistant, Sale, Humanities, Research, Securities Act of 1933, Immunology, Neoplasm, U.S. Securities and Exchange Commission, Name, Division, Antibody, Company, Review, Learning, Therapy, Mouse, Forward-looking statement, Cancer, OTC, Exercise, CEO, Technology, Goal, Lymphatic system, University, Association of American Universities, Security (finance), Association, Proxy, SEC, Prospectus, Hematological Cancer Research Investment and Education Act, CAR, Toxicity, Medical imaging, Vaccine, Pharmaceutical industry, Chemistry

WEXFORD, Pa., Sept. 21, 2022 /PRNewswire/ -- Coeptis Therapeutics, Inc. (OTC PINK: COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, today announced entry into an exclusive license agreement with the University of Pittsburgh for the rights to a chimeric antigen receptor T cell (CAR T) technology – SNAP-CAR – designed to target multiple antigens simultaneously and potentially address a range of hematologic and solid tumors, including breast and ovarian cancer. Completion of the exclusive license agreement for SNAP-CAR follows Coeptis' entry into an option agreement with the University of Pittsburgh announced in May 2022.

Key Points: 
  • Completion of the exclusive license agreement for SNAP-CAR follows Coeptis' entry into an option agreement with the University of Pittsburgh announced in May 2022.
  • This approach has proven effective in certain cancer types but limits the applicability of those CAR T therapies.
  • SNAP-CAR is designed to be a "universal" CAR T cell therapy platform that can be adapted to different cancer indications.
  • "SNAP-CAR represents a potential breakthrough in CAR T approaches and a significant addition to Coeptis' expanding cell therapy product portfolio," said Dave Mehalick, President and CEO of Coeptis Therapeutics.

OncoNano Medicine Announces Oral Presentation of Phase 2 Study Data at the World Molecular Imaging Congress 2022

Retrieved on: 
Wednesday, September 14, 2022
Research, Surgery, Clinical Trials, Biotechnology, Health, Pharmaceutical, Other Science, Science, Oncology, Cancer, Therapy, Tumor board review, Surgical oncology, Stimulator of interferon genes, Department, Stimulator, MD, Patient, Medical imaging

OncoNanos lead development candidate is pegsitacianine, a novel fluorescent nanoprobe using the ON-BOARD platform, that is currently under study in Phase 2 clinical trials as a real-time surgical imaging agent for use in multiple cancer surgeries.

Key Points: 
  • OncoNanos lead development candidate is pegsitacianine, a novel fluorescent nanoprobe using the ON-BOARD platform, that is currently under study in Phase 2 clinical trials as a real-time surgical imaging agent for use in multiple cancer surgeries.
  • ONM-501, OncoNanos second development program, is a next generation STING (STimulator of INterferon Genes) agonist that is advancing towards a first in human trial in the first half of 2023.
  • Pegsitacianine and ONM-501 have been supported by grants received from the Cancer Prevention Research Institute of Texas.
  • View source version on businesswire.com: https://www.businesswire.com/news/home/20220914005116/en/

Prana Thoracic Announces That Its Subsidiary Receives $3 Million CPRIT Grant to Develop a Minimally Invasive Device for Early Interception of Lung Cancer

Retrieved on: 
Monday, August 22, 2022
Surgery, Oncology, Health, Start-Up, Medical Devices, Professional Services, Technology, Other Health, Lung cancer, Texas Legislature, CEO, Technology, Cancer prevention, Cancer, Research institute, Survival, Cancer Prevention and Research Institute of Texas, Disease, Invention, Solution, Physician, Diagnosis, Lung cancer staging, Lung, Organization, MD, Johnson & Johnson, Surgical oncology, Lone Star, Patient, Pharmaceutical industry, Medical imaging, Surgery, Oncology, Health, Start-Up, Medical Devices, Professional Services, Technology, Other Health

Prana Thoracic is a medical device company developing the first minimally invasive lung tissue excision tool for early interception of lung cancer.

Key Points: 
  • Prana Thoracic is a medical device company developing the first minimally invasive lung tissue excision tool for early interception of lung cancer.
  • Lung cancer is the leading cause of cancer death in the U.S., making up almost 25% of all cancer deaths.
  • Houston-based medical device startup Prana Thoracic, Inc. is dedicated to developing solutions for the detection and intervention of early-stage lung cancer.
  • Prana Thoracic is developing the first minimally invasive, tissue-sparing nodulectomy tool for early interception of suspicious pulmonary nodules.

DynamiCure Announces IND Clearance to Advance First Antibody Candidate from its DC-6001 Anti-CD93 Program into Clinical Development

Retrieved on: 
Monday, August 22, 2022
University, Safety, Cancer, Surgical oncology, Research, Tumor microenvironment, Autoimmune disease, IND, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Part, Doctor of Philosophy, Associate, Â, Food, Science, Laboratory, United Technologies, CD93, MD, GLOBE, Epitope, Health, Hypoxia (medical), FDA, Yale University, Immune system, Therapy, News, Adult, Hypoxia, Patient, Cancer research, Pharmaceutical industry

The study is designed to evaluate the safety and efficacy of DCBY02 in adult patients with a wide range of advanced cancers.

Key Points: 
  • The study is designed to evaluate the safety and efficacy of DCBY02 in adult patients with a wide range of advanced cancers.
  • DynamiCure plans to submit the IND for the second monoclonal antibody from the DC-6001 program, DCSZ11, in the fourth quarter of 2022.
  • I look forward to continuing to collaborate with the DynamiCure team as they work to advance this and additional internal programs.
  • DynamiCure is employing a platform-agnostic approach to discover and develop therapeutics designed to address significant unmet medical needs in oncology and autoimmune disease.

Leap Therapeutics' Board of Directors Member Dr. Monica Bertagnolli Appointed as the Director of the National Cancer Institute

Retrieved on: 
Friday, August 12, 2022
Hospital, ASCO, BeiGene, CEO, NewYork-Presbyterian Hospital, American Society of Clinical Oncology, Division, Dana–Farber Cancer Institute, SEC, Leadership, Cancer, National academy, Board, Director, LLC, Colorectal Cancer Alliance, Cancer Breakthroughs 2020, Clinical trial, Brigham and Women's Hospital, EDGAR, Patient, Therapy, NCI, Harvard Medical School, Surgical oncology, DKK1, Weill Cornell Medicine, National Academy of Medicine, National Cancer Institute, Alliance for Clinical Trials in Oncology, Nasdaq, MD, National, Dana, Pharmaceutical industry, LEAP

CAMBRIDGE, Mass., Aug. 12, 2022 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics today announced that its Board member, Monica Bertagnolli, MD, has been appointed as the 16th Director of the National Cancer Institute (NCI) by the Biden administration. Dr. Bertagnolli becomes the first woman director of the institute since its inception in 1937. Effective with her appointment, Dr. Bertagnolli will transition off Leap's Board of Directors.

Key Points: 
  • Dr. Bertagnolli becomes the first woman director of the institute since its inception in 1937.
  • Effective with her appointment, Dr. Bertagnolli will transition off Leap's Board of Directors.
  • Dr. Bertagnolli is currently a professor of surgery at Harvard Medical School, and an associate surgeon at Brigham and Women's Hospital and Dana-Farber Cancer Institute.
  • Dr. Bertagnolli has served on numerous committees and boards including the Board of Directors for ASCO and the National Academy of Medicine's National Cancer Policy Forum.

The Cancer Support Community Applauds the Appointment of Dr. Monica Bertagnolli to Director of the National Cancer Institute

Retrieved on: 
Wednesday, August 10, 2022
Hospital, Cancer Support Community, CEO, GLOBE, Division, Dana–Farber Cancer Institute, Clinical trial, Leadership, Cancer, Learning, Cancer Breakthroughs 2020, Society, Knowledge, Research, American Society of Clinical Oncology, Patient, Health policy, NCI, Harvard Medical School, International Food Protection Training Institute, United Nations International Research and Training Institute for the Advancement of Women, DARPA, Surgical oncology, CSC, Science, National Cancer Institute, MD, Public policy, National, Medicine, Brigham

WASHINGTON, D.C., Aug. 10, 2022 (GLOBE NEWSWIRE) -- The Cancer Support Community (CSC) enthusiastically supports President Bidens selection of Monica Bertagnolli, MD to the position of director of the National Cancer Institute (NCI).

Key Points: 
  • WASHINGTON, D.C., Aug. 10, 2022 (GLOBE NEWSWIRE) -- The Cancer Support Community (CSC) enthusiastically supports President Bidens selection of Monica Bertagnolli, MD to the position of director of the National Cancer Institute (NCI).
  • Bertagnolli is a professor of surgery at Harvard Medical School and serves as chief of the Division of Surgical Oncology at Brigham and Womens Hospital and Dana-Farber Cancer Institute.
  • CSC anticipates fruitful collaboration with Dr. Bertagnolli and the NCI moving forward, ushering in an exciting period of cancer research.
  • CSC furthers its focus on patient advocacy through its Cancer Policy Institute, informing public policy in Washington, D.C. and across the nation.

PMB & UChicago Medicine break ground on $121 million multispecialty care facility in Crown Point, Indiana

Retrieved on: 
Wednesday, August 10, 2022
Multimedia, Medicine, Hospital, Crown Point, Indiana, Medical Affairs Bureau, Business development, Chicago (franchise), Degenerative disease, Cardiology, Office, Corn dog, Working dog, Research, University of Chicago Medical Center, SF, Patient, Quality of life, PET, View, Radiation, Surgical oncology, Architecture, Blog, I-65, The One, Neuroscience, Elective surgery, University of Chicago, Dog, University, Physician, PMB, MD, Perkins and Will, MRI, Pediatrics, City, Health care, Pharmaceutical industry, Health insurance, Medical imaging

CROWN POINT, Ind., Aug. 10, 2022 /PRNewswire/ -- PMB along with The University of Chicago Medicine broke ground on a new two-story, 130,000-square-foot multispecialty care center and micro-hospital in Northwest Indiana for what will be the academic health system's largest off-site facility and its first freestanding building in Indiana. The $121 million state-of-the-art care center, at I-65 and 109th Avenue in Crown Point, is expected to open in spring of 2024.

Key Points: 
  • CROWN POINT, Ind., Aug. 10, 2022 /PRNewswire/ --PMB along with The University of Chicago Medicine broke ground on a new two-story, 130,000-square-foot multispecialty care center and micro-hospital in Northwest Indiana for what will be the academic health system's largest off-site facility and its first freestanding building in Indiana.
  • The $121 million state-of-the-art care center, at I-65 and 109th Avenue in Crown Point, is expected to open in spring of 2024.
  • PMB & UChicago Medicine break ground on $121 million multispecialty care facility in Crown Point, Indiana
    During the on-site groundbreaking ceremony on August 3, 2022, hospital leaders and Crown Point's mayor spoke about the benefits of the new care facility to the community and broader Northwest Indiana region.
  • The multispecialty care facility adds to the presence UChicago Medicine already has through smaller medical offices in Northwest Indiana in Munster, Merrillville, Westville and Schererville.

Alaunos Therapeutics Appoints Abhishek Srivastava, Ph.D. as Vice President, Technical Operations

Retrieved on: 
Thursday, August 4, 2022
Regulation of tobacco by the U.S. Food and Drug Administration, Intellectual property, U.S. Securities and Exchange Commission, Risk, Industry, Forward-looking statement, GLOBE, Division, MD Anderson Cancer Center, University of Louisville School of Medicine, Private Securities Litigation Reform Act, TIL, TCR, National, Security (finance), TP53, Research, Sleeping Beauty, University, Therapy, NCI, Company, EGFR, Biotechnology, KRAS, Surgical oncology, National Cancer Institute, Food, Pharmaceutical industry, Immunology

HOUSTON, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (Alaunos or the Company) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company, today announced the appointment of Abhishek Srivastava, Ph.D. as Vice President of Technical Operations.

Key Points: 
  • HOUSTON, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (Alaunos or the Company) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company, today announced the appointment of Abhishek Srivastava, Ph.D. as Vice President of Technical Operations.
  • Abhi brings extensive experience in cell therapy technical operations, and I am pleased to welcome him to our team, commented Kevin S. Boyle, Sr., Chief Executive Officer of Alaunos.
  • Abhi will add immediate value as we plan to expand our manufacturing capabilities and set Alaunos up for continued success.
  • Abhishek Srivastava, Ph.D., Vice President of Technical Operations added I am thrilled to join Alaunos at this exciting moment in its development.

Navidea Biopharmaceuticals Announces Publication of Study Examining Use of Tc99m Tilmanocept for Lymphatic Mapping and Sentinel Lymph Node Biopsy in Melanoma and Oral Cancer in Australia

Retrieved on: 
Monday, August 1, 2022
Research, Medical Devices, Surgery, Publishing, Communications, Biotechnology, Pharmaceutical, Health, Science, Oncology, Sentinel, Literature, Melanoma, Review, NYSE American, University, FRCSE, MBBS, SLN, Manuscript, United Kingdom, Otorhinolaryngology, Lymph, Research, Securities Exchange Act of 1934, CM, Decision-making, Macrophage, Coronavirus, Surgical oncology, SEC, Securities Act of 1933, PMID, Disease, Neck, Annual report, Lists of World Heritage Sites, Risk, Health, Forward-looking statement, NYSE, History, Biopharmaceutical, Principal, Technetium-99m, Oral cancer, B cell, Patient, Department, Faculty, Pharmaceutical industry, FRACS, Sentinel lymph node, Medicine, Lymph node, EU, Technetium (99mTc) tilmanocept

Despite this widespread acceptance, several different radiocolloids and dyes have been used, resulting in a non-standardized method of localizing and retrieving sentinel lymph nodes.

Key Points: 
  • Despite this widespread acceptance, several different radiocolloids and dyes have been used, resulting in a non-standardized method of localizing and retrieving sentinel lymph nodes.
  • The use of Tc99m tilmanocept as a radiopharmaceutical for SLNB in CM and OCSCC has not been studied in Australia to date.
  • This prospective study had as its aim the investigation of Tc99m tilmanocept use to evaluate its application, suitability, and reliability in an Australian setting.
  • Tc99m tilmanocept also demonstrated high tissue specificity (100%), with lymph nodal tissue confirmed histologically, with no false positives.

ProtoKinetix Successfully Completes Phase 1 Clinical Trials for the Treatment of Type 1 Diabetes in Islet Cell Transplants

Retrieved on: 
Wednesday, July 20, 2022
Technology, Biotechnology, Nanotechnology, Health, Other Health, Pharmaceutical, Optical, Oncology, Other Science, Research, General Health, Health Technology, Science, Clinical Trials, University, MSM, Canada Research Chair, Doctor of Philosophy, Medicine, Organ transplantation, Surgical oncology, University of Alberta, MD, Patient, FRCSC, AHS, Regenerative medicine, Observation, Dentistry

ProtoKinetix, Incorporated ( www.protokinetix.com ) (the "Company" or "ProtoKinetix") (OTCQB: PKTX ), a clinical-stage biomedical company, today announced that the University of Alberta has successfully completed Phase 1 clinical trial enrollment for the treatment of type 1 diabetes in islet cell transplants.

Key Points: 
  • ProtoKinetix, Incorporated ( www.protokinetix.com ) (the "Company" or "ProtoKinetix") (OTCQB: PKTX ), a clinical-stage biomedical company, today announced that the University of Alberta has successfully completed Phase 1 clinical trial enrollment for the treatment of type 1 diabetes in islet cell transplants.
  • The molecule, PKX-001 (AAGP) successfully achieved, to date, the primary safety objectives.
  • The trial is continuing with observation of the latest enrolled patients to monitor secondary objectives over the next 6-months.
  • Following this period of follow-up, all secondary objectives will have been evaluated in all patients, and the data will be collated, analyzed, and reported.